The third quarter report of 2014 issued by Gillette Science in the United States showed that net profit increased by 246% year on year
-
Last Update: 2014-10-31
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: great wisdom ashdak news agency October 29, 2014, Gillette science released its 2014 quarterly report on Tuesday According to the financial report, the company's sales in the third quarter of this year reached US $6.04 billion, up 117% year-on-year, the company's net profit reached US $2.73 billion, up 246% year-on-year, and the company's earnings per share reached US $1.67 According to the third quarter report, the sales of the company's antiviral product series increased by 138% year-on-year to US $5.544 billion, of which US $2.9 billion was contributed by the company's hepatitis C drug sovaldi, which was launched at the end of 2013 In addition, the company's anti AIDS drug, stribild, also increased by 128% to $328 million year on year In cardiovascular products, the company's sales reached 278 million US dollars in the third quarter of this year, up 11% year on year Ranexa sales increased 14% year-on-year to $132 million
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
